Compliance updated on Jun 19, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Candel Therapeutics Inc

CADL ✗ NOT COMPLIANT ☆ Track — members

Nasdaq · Healthcare · Biotechnology & Medical Research ·

USA Small Cap Analyst: BUY

Last Close

$11.72

▼ -0.68%

Market Cap $896.80M · Vol 558.95K

Key Metrics

P/E Ratio

N/A

FWD: N/A

Market Cap

$896.80M

Small Cap

Div Yield

N/A

EPS Growth

-62.30%

YoY

RSI (14)

76.51

Momentum

Beta

-0.47

vs Market

52W High

$11.94

1.84% below

52W Low

$4.37

168.19% above

Volume

558.95K

Avg 350.17K

P/B

5.97

Price-to-book

ROE

-44.87%

Return on equity

Free Float

84.48%

Public shares

Shariah Compliance8 STANDARDS

✗ Candel Therapeutics Inc (CADL) stock is currently not Shariah compliant

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See which standards it fails, the exact ratios behind the verdict, and halal alternatives. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does CADL pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

+10.67%

+18.74%

+31.54%

+106.34%

YTD

+107.43%

+94.04%

+893.22%

+54.41%

Financials & Valuation

TTM · Annual

Total Revenue	$0.00
Net Income	$-38,182,000.00
Revenue Growth (YoY)	N/A
Gross Margin	N/A
Operating Margin	N/A
Net Profit Margin	N/A
ROE	-44.87%
ROA · ROIC	-32.91% · N/A

P/E Ratio	N/A
Forward P/E (FY1)	N/A
PEG Ratio	N/A
P/S	N/A
P/B	5.97
P/FCF	N/A
EPS Growth	-62.30%
Outstanding Shares	76.52M

Technical Indicators

50-Day SMA	$9.67
200-Day SMA	$6.80
RSI (14)	76.51
Beta	-0.47
52-Week High	$11.94
52-Week Low	$4.37

Volume Today	558.95K
Avg Daily Volume (30D)	350.17K
Relative Volume	1.60x
Volatility (10D)	49.51
Volatility (30D)	54.88
Free Float	84.48%

Analyst Consensus

BUY

Current Price $11.72

Mean Target $20.88

52W Low$4.37 52W High$11.94

Current

Target

$4.37 $11.94

Current Analyst target

+78.11% upside potential · 9 analysts

Identifiers

ExchangeNasdaq

FIGIBBG00N0D4Z80

ISINUS1374041093

CountryUnited States of America

Sub-IndustryBiotechnology & Medical Research (NEC)

Earnings DateNov 13, 2026

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

LONN.S Lonza Group AG -1.78% RVMD Revolution Medicines Inc +0.85% ONC BeOne Medicines AG -2.40% 068270.KS Celltrion Inc -0.50% ABVX Abivax SA -2.05%

Company Profile

Candel Therapeutics, Inc. is a BLA-ready clinical-stage biopharmaceutical company focused on developing off-the-shelf multimodal biological immunotherapies that elicit an individualized, systemic antitumor immune response to help patients fight cancer. CAN-2409 is the lead product candidate from the adenovirus platform. CAN-3110 is the lead product candidate from the herpes simplex virus (HSV) platform and is in an ongoing phase Ib clinical trial in recurrent high-grade glioma. Its enLIGHTEN Discovery Platform is a systematic, iterative HSV-based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapies for solid tumors. CAN-2409, Its advanced multimodal biological immunotherapy candidate, is an investigational, off-the-shelf, replication-defective adenovirus engineered to deliver the herpes simplex virus thymidine kinase (HSV-tk) gene to a patient’s specific tumor and induce an individualized, systemic immune response against the tumor.